Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173


Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.

Tummala R, Diegelman P, Fiuza SM, Batista de Carvalho LA, Marques MP, Kramer DL, Clark K, Vujcic S, Porter CW, Pendyala L.

Oncol Rep. 2010 Jul;24(1):15-24.


Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. doi: 10.1007/s00280-010-1334-9. Epub 2010 May 5.


The role of spermidine/spermine N1-acetyltransferase in endotoxin-induced acute kidney injury.

Zahedi K, Barone S, Kramer DL, Amlal H, Alhonen L, Jänne J, Porter CW, Soleimani M.

Am J Physiol Cell Physiol. 2010 Jul;299(1):C164-74. doi: 10.1152/ajpcell.00512.2009. Epub 2010 Apr 14.


Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: survivin expression overlaps with stem cell markers.

Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, Johnson CS, Rustum YM, Porter CW.

Am J Pathol. 2010 Apr;176(4):1629-38. doi: 10.2353/ajpath.2010.090414. Epub 2010 Feb 4.


Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools.

Bistulfi G, Diegelman P, Foster BA, Kramer DL, Porter CW, Smiraglia DJ.

FASEB J. 2009 Sep;23(9):2888-97. doi: 10.1096/fj.09-130708. Epub 2009 May 5.


Spermidine/spermine-N1-acetyltransferase ablation protects against liver and kidney ischemia-reperfusion injury in mice.

Zahedi K, Lentsch AB, Okaya T, Barone S, Sakai N, Witte DP, Arend LJ, Alhonen L, Jell J, Jänne J, Porter CW, Soleimani M.

Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G899-909. doi: 10.1152/ajpgi.90507.2008. Epub 2009 Jan 22.


Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.

Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K.

J Clin Oncol. 2008 Oct 10;26(29):4851-2; author reply 4852-3. doi: 10.1200/JCO.2008.18.2857. Epub 2008 Sep 8. No abstract available.


Polyamine acetylation modulates polyamine metabolic flux, a prelude to broader metabolic consequences.

Kramer DL, Diegelman P, Jell J, Vujcic S, Merali S, Porter CW.

J Biol Chem. 2008 Feb 15;283(7):4241-51. Epub 2007 Dec 18.


Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.

Hector S, Tummala R, Kisiel ND, Diegelman P, Vujcic S, Clark K, Fakih M, Kramer DL, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2008 Aug;62(3):517-27. Epub 2007 Nov 7.


Functional insights from structural genomics.

Forouhar F, Kuzin A, Seetharaman J, Lee I, Zhou W, Abashidze M, Chen Y, Yong W, Janjua H, Fang Y, Wang D, Cunningham K, Xiao R, Acton TB, Pichersky E, Klessig DF, Porter CW, Montelione GT, Tong L.

J Struct Funct Genomics. 2007 Sep;8(2-3):37-44. Epub 2007 Jun 23.


Polyamine metabolism and tumorigenesis in the Apc(Min/+) mouse.

Berger FG, Kramer DL, Porter CW.

Biochem Soc Trans. 2007 Apr;35(Pt 2):336-9.


Genetically altered expression of spermidine/spermine N1-acetyltransferase affects fat metabolism in mice via acetyl-CoA.

Jell J, Merali S, Hensen ML, Mazurchuk R, Spernyak JA, Diegelman P, Kisiel ND, Barrero C, Deeb KK, Alhonen L, Patel MS, Porter CW.

J Biol Chem. 2007 Mar 16;282(11):8404-13. Epub 2006 Dec 21.


Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS.

J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6.


Spermidine/spermine N1-acetyltransferase overexpression in kidney epithelial cells disrupts polyamine homeostasis, leads to DNA damage, and causes G2 arrest.

Zahedi K, Bissler JJ, Wang Z, Josyula A, Lu L, Diegelman P, Kisiel N, Porter CW, Soleimani M.

Am J Physiol Cell Physiol. 2007 Mar;292(3):C1204-15. Epub 2006 Oct 25.


Immunomodulating drugs for chronic lymphocytic leukaemia.

Chanan-Khan A, Porter CW.

Lancet Oncol. 2006 Jun;7(6):480-8. Review.


Structural and functional evidence for Bacillus subtilis PaiA as a novel N1-spermidine/spermine acetyltransferase.

Forouhar F, Lee IS, Vujcic J, Vujcic S, Shen J, Vorobiev SM, Xiao R, Acton TB, Montelione GT, Porter CW, Tong L.

J Biol Chem. 2005 Dec 2;280(48):40328-36. Epub 2005 Oct 6.


Potent modulation of intestinal tumorigenesis in Apcmin/+ mice by the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase.

Tucker JM, Murphy JT, Kisiel N, Diegelman P, Barbour KW, Davis C, Medda M, Alhonen L, Jänne J, Kramer DL, Porter CW, Berger FG.

Cancer Res. 2005 Jun 15;65(12):5390-8.


Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.

Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, Nilsson LM, Neale G, Kramer DL, Porter CW, Cleveland JL.

Cancer Cell. 2005 May;7(5):433-44.


Metabolic stability of alpha-methylated polyamine derivatives and their use as substitutes for the natural polyamines.

Järvinen A, Grigorenko N, Khomutov AR, Hyvönen MT, Uimari A, Vepsäläinen J, Sinervirta R, Keinänen TA, Vujcic S, Alhonen L, Porter CW, Jänne J.

J Biol Chem. 2005 Feb 25;280(8):6595-601. Epub 2004 Dec 16.


Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase.

Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L.

Mol Cancer Ther. 2004 Jul;3(7):813-22.


Activated polyamine catabolism depletes acetyl-CoA pools and suppresses prostate tumor growth in TRAMP mice.

Kee K, Foster BA, Merali S, Kramer DL, Hensen ML, Diegelman P, Kisiel N, Vujcic S, Mazurchuk RV, Porter CW.

J Biol Chem. 2004 Sep 17;279(38):40076-83. Epub 2004 Jul 13.


Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells.

Kee K, Vujcic S, Merali S, Diegelman P, Kisiel N, Powell CT, Kramer DL, Porter CW.

J Biol Chem. 2004 Jun 25;279(26):27050-8. Epub 2004 Apr 19.


Small interfering RNA suppression of polyamine analog-induced spermidine/spermine n1-acetyltransferase.

Chen Y, Kramer DL, Jell J, Vujcic S, Porter CW.

Mol Pharmacol. 2003 Nov;64(5):1153-9.


Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites.

Subhi AL, Diegelman P, Porter CW, Tang B, Lu ZJ, Markham GD, Kruger WD.

J Biol Chem. 2003 Dec 12;278(50):49868-73. Epub 2003 Sep 23.


The role of mitogen-activated protein kinase activation in determining cellular outcomes in polyamine analogue-treated human melanoma cells.

Chen Y, Alm K, Vujcic S, Kramer DL, Kee K, Diegelman P, Porter CW.

Cancer Res. 2003 Jul 1;63(13):3619-25.


Genomic identification and biochemical characterization of a second spermidine/spermine N1-acetyltransferase.

Chen Y, Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW.

Biochem J. 2003 Aug 1;373(Pt 3):661-7.


A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice.

Frydman B, Porter CW, Maxuitenko Y, Sarkar A, Bhattacharya S, Valasinas A, Reddy VK, Kisiel N, Marton LJ, Basu HS.

Cancer Chemother Pharmacol. 2003 Jun;51(6):488-92. Epub 2003 Apr 15.


Expression of SSAT, a novel biomarker of tubular cell damage, increases in kidney ischemia-reperfusion injury.

Zahedi K, Wang Z, Barone S, Prada AE, Kelly CN, Casero RA, Yokota N, Porter CW, Rabb H, Soleimani M.

Am J Physiol Renal Physiol. 2003 May;284(5):F1046-55. Epub 2003 Jan 28.


Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion.

Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW.

Biochem J. 2003 Feb 15;370(Pt 1):19-28.


Synthesis and evaluation of analogues of 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine as inhibitors of tumor cell growth, trypanosomal growth, and HIV-1 infectivity.

Marasco CJ Jr, Kramer DL, Miller J, Porter CW, Bacchi CJ, Rattendi D, Kucera L, Iyer N, Bernacki R, Pera P, Sufrin JR.

J Med Chem. 2002 Nov 7;45(23):5112-22.


Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin.

Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW.

Biochem J. 2002 Nov 1;367(Pt 3):665-75.


A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2157-66.


Altered levels of growth-related and novel gene transcripts in reproductive and other tissues of female mice overexpressing spermidine/spermine N1-acetyltransferase (SSAT).

Min SH, Simmen RC, Alhonen L, Halmekyto M, Porter CW, Janne J, Simmen FA.

J Biol Chem. 2002 Feb 1;277(5):3647-57. Epub 2001 Nov 14.


Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells.

Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW.

Cancer Res. 2001 Sep 1;61(17):6437-44.


Spermidine/spermine n(1)-acetyltransferase catalyzes amantadine acetylation.

Bras AP, Jänne J, Porter CW, Sitar DS.

Drug Metab Dispos. 2001 May;29(5):676-80.


Spermine deficiency resulting from targeted disruption of the spermine synthase gene in embryonic stem cells leads to enhanced sensitivity to antiproliferative drugs.

Korhonen VP, Niiranen K, Halmekytö M, Pietilä M, Diegelman P, Parkkinen JJ, Eloranta T, Porter CW, Alhonen L, Jänne J.

Mol Pharmacol. 2001 Feb;59(2):231-8.


Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene.

Shi O, Morris SM Jr, Zoghbi H, Porter CW, O'Brien WE.

Mol Cell Biol. 2001 Feb;21(3):811-3.


[Phosphinic analog of methionine inhibits growth of leucosis cell L1210 and transforms to phosphinic analog of S-adenosylmethionine].

Khomutov RM, Zhukov IuN, Khomutov AR, Khurs EN, Kramer DL, Miller JT, Porter CW.

Bioorg Khim. 2000 Sep;26(9):718-20. Russian.


Dependence of Trichomonas vaginalis upon polyamine backconversion.

Yarlett N, Martinez MP, Goldberg B, Kramer DL, Porter CW.

Microbiology. 2000 Oct;146 ( Pt 10):2715-22.


Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs.

Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW.

J Biol Chem. 2000 Dec 8;275(49):38319-28.


Treatment of cells with the polyamine analog N, N11-diethylnorspermine retards S phase progression within one cell cycle.

Alm K, Berntsson PS, Kramer DL, Porter CW, Oredsson SM.

Eur J Biochem. 2000 Jul;267(13):4157-64.


The polyamine oxidase inhibitor MDL-72,527 selectively induces apoptosis of transformed hematopoietic cells through lysosomotropic effects.

Dai H, Kramer DL, Yang C, Murti KG, Porter CW, Cleveland JL.

Cancer Res. 1999 Oct 1;59(19):4944-54.


Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells.

Kramer DL, Vujcic S, Diegelman P, Alderfer J, Miller JT, Black JD, Bergeron RJ, Porter CW.

Cancer Res. 1999 Mar 15;59(6):1278-86.


Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway.

Kramer DL, Vujcic S, Diegelman P, White C, Black JD, Porter CW.

Biochem Soc Trans. 1998 Nov;26(4):609-14. Review. No abstract available.


Supplemental Content

Loading ...
Support Center